$JNJ Tecvayli (& $LEGN Carvykti) "entering a new era of resetting survival expectations in a cancer historically described as incurable". @ByMadeleineA @ApexOnco from #ASH25 on Majestec-3 https://t.co/yUP2j9tJjj $ACLX $BMY
New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment https://t.co/h2TMrtrufE $GILD $ACLX $JNJ $LEGN #ASH25
$CRBU +175% premarket, opened +30%, now flat. My take on the latest Antler data, via @ApexOnco -> https://t.co/GNYYkqjUsm $ALLO $GILD $ACLX $LEGN
Interesting take on the FcRH5 landscape, which seems to be one of $RHHBY's main oncology R&D areas of interest. $MRNA & $LEGN active here https://t.co/87JPjuwyu5
In 2023 $NVS paid $LEGN $100m for an anti-DLL3 Car-T. First human data at #WCLC25 show that this still a work in progress. Via @ApexOnco -> https://t.co/sXZa93t77h
Plus some other #WCLC25 presentations of note: https://t.co/xavXaIItJu $LEGN $TIL $NVS $BNTX $CADL
Fascinating Evercore ISI webinar going on right now about disconnect between value of Sino deal and what $MRK owes Lanova on the PD-1 x VEGF. In summary: 40% of $588m MRK up front, and 25% of the $300m tech transfer, actually went to Genscript (!) $LEGN
Heads up: a Claudin18.2 Car-T has just been filed for approval*. Via @ApexOnco -> https://t.co/uXpt2keT2W $ALMPF $LEGN $AZN *in China.
@Nicole_Paulk @iskander $LEGN & Starna now in clinical trials with in vivo Car-T https://t.co/0zn7Q65hLK
2 new in vivo Car-T projects just started phase 1: $LEGN LVIVO-TaVec100 -> https://t.co/iWmPbOlcw7 Starna STR-P004 -> https://t.co/FBIj0K4EhR
